GLP-1/GIP Receptor Agonists Significantly Reduce Obstructive Sleep Apnea Severity and Cardiometabolic Risk
[The role of obesity and weight reduction in obstructive sleep apnea].
Abstract
GLP-1/GIP receptor agonists promote weight loss and significantly alleviate obstructive sleep apnea (OSA) severity by reducing the apnea-hypopnea index (AHI) and concurrently lowering cardiometabolic risk.